Brain MRI scans in newly diagnosed advanced lung cancer
Tests brain MRI scans in adults with new advanced lung cancer and no brain symptoms.
Key facts
- Who runs it
- University Medical Center Groningen
- Where
- Groningen, Maastricht, and Scheemda, NetherlandsSee the 3 sites
- Trial code
- Registry title
- Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 13 May 2024
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional
- Treatments tested
- MRI
- Record updated
- 9 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed stage IV non-small cell lung cancer who have no symptoms of brain disease. They will have a brain MRI scan to look for brain disease.
- Age
- 18 years or older
- Sex
- Women and men can join
- Disease stage
- Stage IV (metastatic) non-small cell lung cancer, confirmed by tissue or cell tests, that cannot be treated with treatment meant to remove all of the disease
- Earlier treatment
- No earlier or ongoing treatment for stage IV disease
- Biomarker or test result
- No cancer-driving gene change (for example EGFR, ALK, ROS1, RET, MET, BRAF) that has an approved targeted treatment
Main reasons for not taking part
- Earlier or ongoing treatment for stage IV disease
- Gene change such as EGFR, ALK, ROS1, RET, MET or BRAF with an approved targeted treatment
- Reasons the person cannot have an MRI scan with contrast, as set by the hospital's standard protocol
- Symptoms of brain disease
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Histologically or cytologically confirmed stage IV metastatic NSCLC, not amenable to curative treatment
- Fit for systemic treatment (PS 0-2) according to standard of care
- No symptoms of brain disease disease assessed according to standard clinical care by the thoracic oncologist
Who cannot take part
- Prior/concomitant therapy for stage IV disease
- Oncogenic diver mutation (e.g. EGFR, ALK, ROS1, RET, MET, and BRAF) with approved targeted treatment
- Contraindications for MRI scan with contrast as per standard of care protocol of the institution
Where in Netherlands
- University Medical Center GroningenGroningen, NetherlandsContact: Frederike Bensch, MD, PhDTaking people
- Maastricht UMCMaastricht, NetherlandsContact: Lizza HendriksTaking people
- Ommelander ZiekenhuisgroepScheemda, NetherlandsContact: Alice StaatsTaking people
About the trial
What the trial wants to find out
Patients with newly diagnosed stage IV non-oncogene addicted NSCLC, who are fit for systemic treatment and don't have any symptoms of brain disease will undergo an MRI of the brain to screen for brain disease.
The group in the trial
- Screening populationTreatment being tested
Patients with newly diagnosed stage IV non-oncogene addicted NSCLC, who are fit for systemic treatment and don't have any symptoms of brain disease.
Treatment: MRI
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- ValUe of Screening MRI Brain in Patients With Newly Diagnosed Stage IV Non-oncogene Addicted Non-small Cell Lung CANcer - The VULCAN Trial
- Plain-language title
- Brain MRI scans in newly diagnosed advanced lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 9 June 2026